Retroviral Integration Site Analysis in Hematopoietic Stem Cells

Author(s):  
Olga S. Kustikova ◽  
Christopher Baum ◽  
Boris Fehse
2007 ◽  
Vol 18 (10) ◽  
pp. 895-906 ◽  
Author(s):  
Junko Mitsuhashi ◽  
Satomi Tsukahara ◽  
Rieko Suzuki ◽  
Yumiko Oh-Hara ◽  
Saori Nishi ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4622-4622
Author(s):  
Nadja Grund ◽  
Patrick Maier ◽  
Uwe Appelt ◽  
Heike Allgayer ◽  
Frederik Wenz ◽  
...  

Abstract Hematologic side effects of cancer chemotherapy like myelosuppression are frequently dose-limiting. Lentiviral gene therapy with cytostatic drug resistance gene transfer to human hematopoietic stem cells (CD34+) is a promising approach to overcome this problem. In this context it is of interest if chemotherapy mediated selection has an impact on lentiviral integration site patterns of transduced hematopoietic stem cells (CD34+). Concerning this issue, human CD34+ cells transduced with a lentiviral self-inactivating (SIN) vector encoding MGMTP140K (the O6-BG resistant mutant of O6-methylguanine- DNA methyltransferase) were in vitro treated with the alkylating agent BCNU. For integration site analysis LM-PCR was performed and integration patterns of the treated and untreated CD34+ cells were analyzed and compared with an in silico set of 106 random integrations. We found different integration preferences of the lentiviral vector between either the treated (82 integrations) or the untreated (30 integrations) CD34+ cells and the in silico set: both groups showed chromosomal preferences, a significant bias for integrations in genes (74,4% in the treated, respectively 70% in the untreated to 40% in the in silico group), especially by favouring introns, a random integration distribution regarding transcription start sites (TSS), and most importantly no significant differences concerning the number of integrations in or near cancer genes. Concerning all integration characteristics we could not find significant differences when comparing the untreated with the treated group. In conclusion, the general distribution of lentiviral integrations in either untreated or treated human CD34+ cells showed no distinct differences between both groups but significant differences compared to the in silico integration set. These results suggest that chemoselection of cells lentivirally overexpressing a specific chemoresistence gene might not influence the integration pattern. Therefore chemotherapy pressure seems not to hamper the safety of lentiviral vectors in gene transfer studies.


2006 ◽  
Vol 34 (9) ◽  
pp. 1191-1200 ◽  
Author(s):  
Rhonna M. Gurevich ◽  
Patty M. Rosten ◽  
Maike Schwieger ◽  
Carol Stocking ◽  
R. Keith Humphries

Stem Cells ◽  
2005 ◽  
Vol 23 (8) ◽  
pp. 1050-1058 ◽  
Author(s):  
Wolfgang Wagner ◽  
Stephanie Laufs ◽  
Jonathon Blake ◽  
Christian Schwager ◽  
Xiaolin Wu ◽  
...  

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 783-783
Author(s):  
Susumu Goyama ◽  
Go Yamamoto ◽  
Tomohiko Sato ◽  
Seishi Ogawa ◽  
Shigeru Chiba ◽  
...  

Abstract The ecotropic viral integration site-1 (Evi-1) was first identified as a gene located at the integration site of an ecotropic retrovirus leading to murine myeloid leukemia. Since its identification, Evi-1 has been recognized as one of the dominant oncogenes associated with human myeloid leukemia and myelodysplastic syndrome. Evi-1 is a member of the SET/PR domain family of transcription factors and it contains two separated zinc-finger DNA-binding domains, which recognize cognate DNA sequences respectively. Recently, it was shown that Evi-1 is predominantly expressed in hematopoietic stem cells (HSCs), and HSC activity is significantly impaired in Evi-1-deficient embryos, which succumb to the multiple organ defects before birth. In order to investigate a role of Evi-1 in adult hematopoiesis, we generated the mutant mice harboring Cre recombinase recognition sites (loxP sites) flanking exon 4 of the Evi-1 gene (Evi1flox/flox), together with the mice in which the same region was completely deleted (Evi-1−/−). Evi-1−/− mice died around embryonic day 13–16. In Evi-1−/− embryos, Lineage−Sca1+cKit+ cells (LSK cells) and colony forming cells were severely reduced. Furthermore, Evi-1−/− fetal liver cells could not reconstitute hematopoiesis of sublethally irradiated mice in the transplantation experiments, indicating an apparent defect in hematopietic stem/progenitor cells. In contrast, more committed cells was unaffected in Evi-1−/− fetal liver. Then, we ablated Evi-1 by breeding Evi-1flox/flox mice with mice expressing Cre-recombinase under the control of the Tie2 promoter and enhancer, a marker of endothelial and hematopoietic stem cells. These mice virtually phenocopied Evi-1−/− mice, demonstrating that Evi-1 function is distinctly required in Tie2+ cells to establish HSCs. Next, we assessed the requirement of Evi-1 in adult hematopoiesis using an interferon (IFN) -inducible Mx-Cre gene-targeting method, in which floxed alleles can be effectively deleted in hematopoietic cells upon injection of IFN-inducer pIpC. Immediately upon injection of pIpC, platelet counts modestly declined in Evi-1flox/flox/Mx-Cre mice, while white blood cell counts or hemoglobin levels were not affected. Platelet recovery after 5FU-treatment is also delayed in Evi-1-deficient mice compared to the control mice. Furthermore, two weeks after pIpC infection, LSK cells in Evi-1-deficient mice decreased to about half the number of those in the control mice. By 10 weeks, however, LSK cells in these mice began to recover. At this time point, a majority of hematopoietic cells in the bone marrow retained the intact Evi-1 alleles, suggesting that HSCs can not maintain hematopoiesis in the absence of Evi-1 and are outcompeted by a fraction of HSCs that escaped Cre-mediated Evi-1 exicision. Together, these results show that Evi-1 plays an indispensable role not only in the establishment of HSCs during embryogenesis but also in the maintenance of HSCs in adults.


Blood ◽  
2010 ◽  
Vol 115 (13) ◽  
pp. 2610-2618 ◽  
Author(s):  
Alice Gerrits ◽  
Brad Dykstra ◽  
Olga J. Kalmykowa ◽  
Karin Klauke ◽  
Evgenia Verovskaya ◽  
...  

Abstract Clonal analysis is important for many areas of hematopoietic stem cell research, including in vitro cell expansion, gene therapy, and cancer progression and treatment. A common approach to measure clonality of retrovirally transduced cells is to perform integration site analysis using Southern blotting or polymerase chain reaction–based methods. Although these methods are useful in principle, they generally provide a low-resolution, biased, and incomplete assessment of clonality. To overcome those limitations, we labeled retroviral vectors with random sequence tags or “barcodes.” On integration, each vector introduces a unique, identifiable, and heritable mark into the host cell genome, allowing the clonal progeny of each cell to be tracked over time. By coupling the barcoding method to a sequencing-based detection system, we could identify major and minor clones in 2 distinct cell culture systems in vitro and in a long-term transplantation setting. In addition, we demonstrate how clonal analysis can be complemented with transgene expression and integration site analysis. This cellular barcoding tool permits a simple, sensitive assessment of clonality and holds great promise for future gene therapy protocols in humans, and any other applications when clonal tracking is important.


Sign in / Sign up

Export Citation Format

Share Document